Treatment of Left Frontal Meningioma
Complete surgical resection remains the primary treatment for left frontal meningioma when feasible, with stereotactic radiosurgery (SRS) serving as an effective alternative for surgically inaccessible tumors or as adjuvant therapy for residual disease. 1
Treatment Algorithm Based on Clinical Scenario
For Newly Diagnosed, Accessible Tumors
Pursue gross total resection (GTR) as first-line therapy when the tumor can be safely removed without significant risk to neural or vascular structures. 1, 2 The frontal convexity location typically allows for complete resection with acceptable morbidity. Key surgical principles include:
- Resect the dural attachment/origin to minimize recurrence risk 2
- Use image-guided surgery (frameless stereotaxy) to improve precision and reduce surgical complications 2
- Consider preoperative embolization for large, highly vascular tumors to reduce intraoperative bleeding 2
Common pitfall: Leaving dural attachment behind significantly increases recurrence rates, particularly important in frontal convexity meningiomas where complete dural resection is usually achievable.
For Surgically Challenging or Residual Disease
Stereotactic radiosurgery is recommended as definitive treatment for WHO grade 1 meningiomas that are surgically inaccessible or when patient factors preclude surgery. 1 SRS achieves:
- 10-year local control rates of 71-100% 1
- 10-year progression-free survival of 55-97% 1
- Low toxicity rates with neurological preservation in 80-100% of cases 3
Dosing specifications: Deliver 12-15 Gy in a single fraction for small tumors (<3 cm diameter) 1, 4
For Subtotal Resection or Recurrence
Adjuvant radiation therapy should be considered for:
- WHO grade 2/3 tumors regardless of resection extent 2, 4
- Incomplete resection of grade 1 tumors with documented residual disease 4
- Recurrent disease after prior GTR 2
Fractionated radiotherapy dosing: 45-54 Gy for WHO grade 1-2 tumors; 54-60 Gy in 1.8-2.0 Gy fractions for WHO grade 3 tumors 4
Molecular Considerations
While no molecular targets have reached clinical standard-of-care status (ESCAT level I), molecular profiling may guide treatment decisions in recurrent or aggressive cases. 5 The 2025 EANO guidelines identify mTOR pathway activation and NF2 alterations as investigational targets (ESCAT II), though these should not alter standard surgical or radiation approaches for newly diagnosed frontal meningiomas.
Imaging for Treatment Planning
MRI with and without contrast is the primary imaging modality for surgical planning and follow-up. 6 For radiation therapy planning, particularly in cases with suspected residual disease, 68Ga-DOTATATE PET/CT provides superior tumor delineation compared to MRI alone, allowing for more precise target definition and potential dose escalation to 66-70 Gy for residual disease. 7, 8
Surveillance Strategy
Post-treatment MRI surveillance intervals depend on WHO grade:
- Grade 1: Every 6-12 months initially, can extend intervals after documented stability 6
- Grade 2-3: More frequent follow-up (every 3-6 months) given higher recurrence risk 6
Critical caveat: The post-radiotherapy MRI serves as the "new baseline" rather than the post-surgical scan when interpreting subsequent imaging changes. 6
Special Considerations for Frontal Location
Frontal meningiomas may present with subtle neuropsychiatric symptoms including personality changes, executive dysfunction, or behavioral disinhibition before causing obvious neurological deficits. 9 Even "asymptomatic" patients may have measurable cognitive impairment that improves after resection. 10 This supports a more aggressive surgical approach for accessible frontal tumors rather than prolonged observation.